Search tips
Search criteria

Results 1-9 (9)

Clipboard (0)

Select a Filter Below

more »
Year of Publication
1.  The efficacy and cost-effectiveness of statins in low-risk patients 
PMCID: PMC3216454  PMID: 22025650
4.  Metabolic Syndrome, Independent of Its Components, Is a Risk Factor for Stroke and Death But Not for Coronary Heart Disease Among Hypertensive Patients in the ASCOT-BPLA 
Diabetes Care  2010;33(7):1647-1651.
To evaluate whether in hypertensive patients the risk of cardiovascular disease is greater in association with the metabolic syndrome (MetS) or the sum of its individual components.
Cox regression analysis models were developed to assess the influence of age, sex, ethnicity, and the individual components of MetS on risk associated with the MetS (using several definitions) of coronary outcomes, stroke, and all-cause mortality.
MetS was significantly associated with coronary outcomes, stroke, and all-cause mortality after adjusting for age, sex, and ethnicity. However, when the model was further adjusted for the individual components, MetS was associated with significantly increased risk of stroke (hazard ratio 1.34 [95% CI 1.07–1.68]) and all-cause mortality (1.35 [1.16–1.58]) but not coronary outcomes (fatal coronary heart disease plus nonfatal myocardial infarction 1.16 [0.95–1.43] and total coronary events 1.06 [0.91–1.24]).
MetS, independent of its individual components, is associated with increased risk of stroke and all-cause mortality but not coronary outcomes.
PMCID: PMC2890375  PMID: 20413525
5.  The Efficacy and Tolerability of ‘Polypills’: Meta-Analysis of Randomised Controlled Trials 
PLoS ONE  2012;7(12):e52145.
To assess the blood pressure and lipid-lowering efficacy and tolerability of ‘polypills’ used in cardiovascular disease prevention trials.
Methodology/Principal Findings
Systematic review and meta-analysis. Search strategy: The Cochrane Central Register of Controlled Trials, Medline, and PubMed databases were searched for eligible trials. Study inclusion criteria: Randomised controlled trials of at least six weeks duration, which compared a ‘polypill’ (that included at least one anti-hypertensive and one lipid-lowering medication) with a placebo (or one active component). Outcome measures: Change from baseline in systolic and diastolic blood pressures, and total and LDL-cholesterol; discontinuation of study medication and reported adverse effects. Of 44 potentially eligible studies, six trials (including 2,218 patients without previous cardiovascular disease) fulfilled the inclusion criteria. Compared with placebo, ‘polypills’ reduced systolic blood pressure by −9.2 mmHg (95% confidence interval (CI): −13.4, −5.0) diastolic blood pressure by −5.0 mmHg (95%CI: −7.4, −2.6), total cholesterol by −1.22 mmol/L (95%CI: −1.60, −0.84) and LDL-cholesterol by −1.02 mmol/L (95%CI: −1.37, −0.67). However, those taking a ‘polypill’ (vs. placebo or component) were more likely to discontinue medication (20% vs 14%) (Odds ratio: 1.5 (95% CI: 1.2, 1.9)). There was no significant difference in reported adverse effects amongst those on a ‘polypill’ (36% vs. 28%) (OR: 1.3 (95%CI: 0.7, 2.5)). There was high statistical heterogeneity in comparisons for blood pressure and lipid-lowering but use of random-effects and quality-effects models produced very similar results.
Compared with placebo, the ‘polypills’ reduced blood pressure and lipids. Tolerability was lower amongst those on ‘polypills’ than those on placebo or one component, but differences were moderate. Effectiveness trials are needed to help clarify the status of ‘polypills’ in primary care and prevention strategies.
PMCID: PMC3526586  PMID: 23284906
6.  Approach to postoperative fever in pediatric cardiac patients 
Fever in the postoperative period in children undergoing surgery for congenital heart disease is fairly common and tends to cause anxiety to both the surgeon and the patient. Such fever is associated with the metabolic response to trauma, systemic response to the cardiopulmonary bypass, hypothermia, presence of drainage tubes, drugs, blood transfusion as well as infections. Establishing the diagnosis requires proper assessment of the patient with focused history, targeted physical examination and judicious use of investigations with the knowledge of the common causes.
PMCID: PMC3327019  PMID: 22529605
C0 ardiac surgery; fever; postoperative
7.  Effect of Majja Basti (therapeutic enema) and Asthi Shrinkhala (Cissus quadrangularis) in the management of Osteoporosis (Asthi-Majjakshaya)  
Ayu  2012;33(1):110-113.
Osteoporosis is a systemic disorder that affects entire skeleton, which is a metabolic bone disease characterized by low bone mass and microarchitectural deterioration of the skeleton, leading to enhanced bone fragility and a consequent increase in fracture risk. In Ayurveda, it can be correlated with Asthi-Majjakshaya. Basti (therapeutic enema) is the prime therapy for Asthi related diseases and Asthi Shrinkhala (Cissus quadrangularis) is the drug which is being used for strengthening of bone by traditional Vaidya since long. It has been selected for oral administration. In clinical trial, 12 patients treated with Majja Basti along with Asthi Shrinkhala pulp capsules and results are very encouraging.
PMCID: PMC3456847  PMID: 23049194
Asthi Shrinkhala; Asthi-Majjakshaya; Majja Basti; Osteoporosis
9.  Case report: Acute hepatitis E infection with coexistent glucose-6-phosphate dehydrogenase deficiency 
Hepatitis E virus is one of the leading causes of acute viral hepatitis in India but usually manifests as a mild self-limiting illness. Viral hepatitis in the presence of glucose-6-phosphate dehydrogenase (G6PD) deficiency may be associated with complications such as severe anemia, hemolysis, renal failure, hepatic encephalopathy and even death. The incidence of G6PD deficiency in the general population of northern India is reported to be between 2.2% and 14%. Despite both hepatitis E infection and G6PD deficiency being common, their impact on patient illness has only recently been reported. The present study reports a case of severe hemolysis in a patient with G6PD deficiency and hepatitis E infection.
PMCID: PMC2094938  PMID: 18159462
Glucose-6-phosphate dehydrogenase; G6PD; Hemolysis; Hepatitis E

Results 1-9 (9)